PT-141
A melanocortin receptor agonist approved as Vyleesi for hypoactive sexual desire in women.
Back to all peptides
✨ real molecule sketch
Vendor listed this name?
PT-141
Research suppliers reuse acronyms and blend names—confirm identity before assuming you know the compound.
Pharmacokinetic snapshot
Reference values from published sources—not prescribing or dosing advice. Cosmetic INCI peptides do not belong here; injectable and prescription contexts only.
- Half-life
- ~2 hours
- Typical dose range
- 0.5–2 mg
- Common frequency
- As needed (FDA-approved Vyleesi)
Source: DailyMed Vyleesi
Structure (cute edition)
✨ real molecule sketch
This peptide is a short chain of about 4 amino acids—think of it as a tiny protein necklace on your label.
INCI: PT-141 · ~4 amino acids in our simplified view
FDA label data
Sourced from OpenFDA drug labels (public domain). Not medical advice.
Brand names: Vyleesi
Manufacturer: Cosette Pharmaceuticals, Inc.
Indications
1 INDICATIONS AND USAGE VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or…
Research & public records
Counts and links from public databases (PubMed, ClinicalTrials.gov, Wikidata, NIH drug nomenclature). Educational only — not medical advice.
Knowledge base: chemical compound — Wikipedia
PubMed: 93 indexed papers (search PubMed)
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. · International journal of molecular sciences
- Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions. · Expert opinion on pharmacotherapy
- Bremelanotide.
- Melanocortins in the treatment of male and female sexual dysfunction. · Current topics in medicinal chemistry
- Melanocortin receptors, melanotropic peptides and penile erection. · Current topics in medicinal chemistry
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. · The journal of sexual medicine
- Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. · Peptides
- Gateways to clinical trials. · Methods and findings in experimental and clinical pharmacology
Clinical trials: 10 studies on ClinicalTrials.gov (view search)
- Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran · COMPLETED
- Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder · COMPLETED
- A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) · COMPLETED
- A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity · ACTIVE_NOT_RECRUITING
- Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk · COMPLETED
- Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder · COMPLETED
- 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder · COMPLETED
- Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) · COMPLETED
ChEMBL: BREMELANOTIDE · max phase 4.0
RxNorm names: 0.3 ML bremelanotide 5.83 MG/ML Auto-Injector [Vyleesi] (RxNav)
DailyMed labels: 1 SPL
What brands say it does
PT-141 (bremelanotide) works centrally on melanocortin-4 receptors—not by blood flow like PDE5 drugs. FDA-approved as a nasal spray (Vyleesi). Research-grade PT-141 sold online is not the same as the prescription product.
Where you’ll find it
Prescription Vyleesi; research vendors sell unapproved versions.
Other names you might see
Bremelanotide
Vyleesi
Melanotan II derivative
Compare with similar peptides
Similar peptides
Educational only—not medical advice. We do not sell peptides. Unregulated research chemicals carry serious purity and legal risks.